Skip to main content

Table 1 Baseline clinical characteristics of the two groups

From: Association between increased serum alkaline phosphatase and the coronary slow flow phenomenon

  CSFP group (n = 64) Control group (n = 50) P value
Age (years) 58.6 ± 7.9 57.4 ± 8.4 0.25
Males, n(%) 29(45.3) 24(48.0) 0.85
BMI, (kg/m2) 24.7 ± 3.2 25.2 ± 5.3 0.59
Current smoker, n(%) 9(14.1) 6(12.0) 0.79
Dyslipidemia, n (%) 10(15.6) 6(12.0) 0.79
Diabetes mellitus, n(%) 9(14.1) 5(10.0) 0.58
systolic blood pressure, (mmHg) 123.7 ± 15.0 125.4 ± 13.2 0.62
Diastolic bloodpressure, (mmHg) 77.7 ± 9.4 81.7 ± 10.9 0.11
Medications
 Aspirin, n(%) 40(62.5) 32(64.0) 0.29
 Statin, n(%) 38(59.4) 32(64.0) 0.70
 ACEI/ARB, n(%) 8(12.5) 9(18.0) 0.44
 CCB, n(%) 6(9.4) 7(14.0) 0.56
 Nitrates, n(%) 36(6.3) 30(60.0) 0.71
  1. Values are mean ± standard deviation or numbers with percentages in parentheses
  2. ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin II receptor blocker, CCB calcium antagonist